DES market share decline prompts Boston update
This article was originally published in Clinica
Boston Scientific lowered its sales guidance for 2005 at an analyst meeting during the EuroPCR (Paris Course on Revascularisation) conference in Paris this week, indicating that its worldwide market share in drug-eluting stents will probably not be 58-59% as previously expected. Sales of its Taxus DES are now likely to be $2.6-2.8bn for the year, representing a market share of 52-55%. The company said group sales would probably increase by 13-17% to $6.4-6.6bn. Prior predictions were in the range of $6.4-6.7bn.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.